Join to View Full Profile
601 Elmwood AveURMC Box 605; Room 6-8521Rochester, NY 14642
Phone+1 585-275-7854
Fax+1 585-275-9953
Dr. Goodman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Andrew Goodman is a neurologist based in Rochester, NY, specializing in neuroimmunology and multiple sclerosis. He completed his medical education at Rutgers New Jersey Medical School, followed by a neurology residency at the Icahn School of Medicine at Mount Sinai and a post-doctoral fellowship at the NIH Clinical Center. His expertise includes general neurology, multiple sclerosis, neuroimmunology, neurohospitalist roles, and experimental therapeutics. Dr. Goodman has contributed to various publications and clinical trials related to multiple sclerosis. He received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR in 2012.
Education & Training
National Institutes of Health Clinical CenterPost-Doctoral Fellowship, Neuroimmunology & Multiple Sclerosis, 1983 - 1988
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Neurology, 1979 - 1983
Rutgers New Jersey Medical SchoolClass of 1979
Certifications & Licensure
NY State Medical License 1981 - 2025
MD State Medical License 1985 - 1988
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis Start of enrollment: 2005 Apr 01
- Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS Start of enrollment: 2008 Mar 01
- Lubiprostone in Patients With Multiple Sclerosis Associated Constipation Start of enrollment: 2010 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsDISCOntinuation of disease-modifying therapies in MS: The DISCOMS extension trial.John R Corboy, Robert J Fox, Gary Cutter, Eric Engebretson, Aaron Miller
Multiple Sclerosis. 2025-02-01 - 4 citationsDisease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.Dejan Jakimovski, Katelyn S Kavak, Patricia K Coyle, Andrew D Goodman, Malcolm Gottesman
Journal of Neurology. 2024-02-01 - 23 citationsHigh-dose vitamin Dsupplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial.Sandra D Cassard, Kathryn C Fitzgerald, Peiqing Qian, Susan A Emrich, Christina J Azevedo
Eclinicalmedicine. 2023-05-01
Press Mentions
NeuroGenesis Receives FDA Clearance for Phase IIb StudyApril 24th, 2023
#AAN2019 — Ibudilast Slows Brain Atrophy in PPMS but Not SPMS Patients, Phase 2b Trial ShowsApril 4th, 2019
MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (Ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, PennsylvaniaMarch 24th, 2019- Join now to see all
Grant Support
- Public Prevention Health Fund: Community Transformation GrantsNational Center For Chronic Disease Prev And Health Promo2011
- Antegren/ Intramuscular Interferon Beta 1A In MSNational Center For Research Resources2000–2002
- Study Of IV Antegren In Patients With MS During Acute ExaserbationNational Center For Research Resources1998–2002
- Study To Assess Pharmacokinetics Of ESC Dose Of Fampridinein In MS PatientsNational Center For Research Resources1998–2001
- Longterm OPEN Label Study To Evaluate Safety Of Copaxone In Multiple SclerosisNational Center For Research Resources1996–1997
- Quantitative Assessment Of Fampridine For Motor Deficits In MSNational Center For Research Resources1996
- Phase II Titration Study Of Fampridine Administered BID In Multiple SclerosisNational Center For Research Resources1996
- Lymphocyte B-Adrenergic Receptors In Multiple SclerosisNational Center For Research Resources1992–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
